US · Basic Materials · Specialty Chemicals
EPS came in at 1.57 against a street estimate of 1.54 — a beat of 1.9%.
Analysts rate Balchem Corporation a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $213.50.
CONFIDENT Balchem delivered a record third quarter with broad-based growth, expanding margins, strong cash generation and improving Animal Nutrition performance. Management expects healthy year-over-year fourth-quarter growth but provided no formal revenue or EPS guidance. Q3 FY26 Management discussed U.S., European, Middle Eastern and Asian demand, but did not provide consolidated regional results. Analysts focused on margin mix, Animal Nutrition sustainability, inventory, clinical opportunities and partnerships. Management emphasized favorable portfolio mix, deliberate safety stock, product launches and continued science-led marketing. 2026-10-23…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.57% |
| Vanguard Portfolio Management, LLC | 6.97% |
| Vanguard Capital Management, LLC | 4.53% |
| State Street Corp | 4.02% |
| Geode Capital Management, LLC | 3.52% |
| Conestoga Capital Advisors, LLC | 3.41% |
| Wasatch Advisors LP | 3.30% |
| Morgan Stanley - Brokerage Accounts | 2.62% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 net sales were $290,658, up from $267,558 in Q3 2025. • Q3 2026 net earnings were $46,728, compared with $40,289; diluted | 2026-10-23 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net sales were $290.7 million, up 8.6% year over year and a quarterly record. • GAAP net earnings were $46.7 million, up | 2026-10-23 |
| Quarterly report · Q2 2026 BALCHEM CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Sales (6M 2026): $554.7 million vs $506.0 million (2025) — up 9.6% • Net Earnings | 2026-07-31 |
| Results announced · Q3 2026 BALCHEM CORPORATION Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net sales: $284.0 million, up 11.2% year-over-year • Net earnings: $44.6 million, u | 2026-07-31 |
| Material agreement · Q3 2026 BALCHEM CORPORATION (BCPC) – FORM 8-K SUMMARY As of July 24, 2026 --- HEADLINE NUMBERS • Revolving credit facility increased from $550 million to $ | 2026-07-27 |
| Shareholder vote results · Q2 2026 BALCHEM CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held June 18, 2026 • Company trades under ticker BCPC on Na | 2026-06-22 |
| Quarterly report · Q1 2026 BALCHEM CORPORATION – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Sales: $270.7M (Q1 2026) vs. $250.5M (Q1 2025) — 8.0% increase • Net Earnings | 2026-04-30 |
| Results announced · Q2 2026 BALCHEM CORPORATION Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net sales: $270.7 million, up 8.1% from $250.5 million in Q1 2025 • Net earnings: $4 | 2026-04-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.40 / share ex-date Dec 31, 2026 · pay Jan 15, 2027 | 2026-12-31 |
| Dividend | $0.96 / share ex-date Dec 23, 2025 · pay Jan 20, 2026 | 2025-12-23 |
| Announcement | Date |
|---|---|
| Board approves new stock repurchase program for up to 4 million shares Balchem Corporation announced two shareholder-friendly actions on December 9-10, 2025: (1) a dividend declaration by the Board of Directors, and (2) approval of a new stock repurchase progra | 2025-12-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Balchem Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.